Last updated: May 25, 2026
Which companies supply AMMONIA N-13 (N-13 ammonia) in the US market?
Suppliers for N-13 ammonia must be identified against the specific FDA-cleared commercial product identity and distribution authorization. “N-13 ammonia” can refer to different commercial preparations (solution strength, sterile fill, container configuration) and different supply models (cyclotron production vs. outsourced radiochemistry manufacturing vs. hospital-operator on-site production).
How do US N-13 ammonia suppliers typically structure supply chains?
- Cyclotron production and target processing (typically by specialty isotope producers)
- Radiochemical synthesis, purification, and sterile formulation
- Quality systems for radiopharmaceutical release and distribution logistics
- Hospital distribution via radiopharmacy networks or direct supply
What counts as a “supplier” for AMMONIA N-13?
- Manufacturer of the radiopharmaceutical drug product (radiochemical + formulation)
- Distributor under the drug’s marketing authorization
- Hospital-based production facility (if operating under appropriate regulatory authorization)
What is the FDA status of AMMONIA N-13 products and why does it affect supplier identification?
Supplier lists must align to the exact marketed product entries (Orange Book is not the right source for radiopharmaceuticals in all cases; some are covered via different regulatory frameworks and product labeling systems). Without the exact FDA marketing identity, there is no way to reliably determine which firms hold the approved manufacturing and marketing roles.
How does labeling identity change the supplier set?
- Solution formulation and activity concentration can differ by product
- Packaging and container closure systems can differ
- Regional distribution authorizations can differ
- Supply may be split between radiopharmacy manufacturers and distributors
What manufacturers produce N-13 ammonia (cyclotron-produced isotope) worldwide?
N-13 ammonia is a cyclotron-driven radiopharmaceutical, so production capacity is constrained by:
- Access to an N-13 generating target and irradiation workflow
- Radiochemical synthesis capacity for ammonia conversion and formulation
- Sterility assurance and radiopharmaceutical QC release capability
- Cold-chain logistics and short half-life operational readiness
What production bottlenecks influence supplier availability?
- Target irradiation capacity and scheduling
- Radiochemical processing slot availability
- Release testing capacity and turnaround time
- Transportation lead time constraints tied to half-life and logistics
Which suppliers can support PET imaging schedules for AMMONIA N-13?
Operational readiness is a differentiator. Even when multiple companies can produce N-13 isotope, only a subset can consistently supply on the cadence required for PET workflows.
What operational capabilities matter for AMMONIA N-13 supply?
- Same-day or short-lead-time fulfillment
- On-time delivery to radiopharmacies and imaging sites
- Lot-by-lot release and documentation turnaround
- Contingency capacity for cyclotron downtime
How do AMMONIA N-13 supply agreements typically work (manufacturer to distributor to hospital)?
Radiopharmaceutical supply is often structured through:
- Direct supply from manufacturer to distributor or radiopharmacy
- Contract radiopharmacy arrangements
- Hospital radiopharmacy fulfillment models
- Temperature-controlled courier and time-window delivery contracts
What terms affect supplier switching risk?
- Qualification and validation cycles for receiving sites
- Release documentation format and QA expectations
- Activity concentration and labeling match requirements
- Delivery window constraints tied to isotope decay
Which suppliers face the highest continuity risks for AMMONIA N-13?
Continuity risk rises when:
- The supplier’s production is tied to one irradiation site
- QC release capacity is constrained
- Distribution depends on a single logistics lane
- Demand spikes exceed operational throughput
How do regulatory and QC constraints affect continuity?
- Manufacturing changes can trigger validation and regulatory review
- QC testing failures can cause short-term suspension of shipments
- Equipment downtime can reduce batch release volume
AMMONIA N-13 supplier comparison: how to benchmark potential vendors
A defensible comparison framework must be tied to product identity and regulated roles, but it typically covers:
Vendor benchmark dimensions
- Product identity match (strength, container configuration, labeling)
- Release testing time and documentation SLAs
- Delivery performance (on-time rate, delivery windows)
- Lot-to-lot consistency metrics (as documented by receiving sites)
- Backup supply availability
What patent and regulatory constraints shape AMMONIA N-13 supplier entry?
Supplier entry can be constrained by:
- Manufacturing process IP (radiochemical synthesis, purification, formulation)
- Regulatory control of manufacturing sites and validated processes
- Authorized distributor roles and supply chain qualifications
How do patent estates influence manufacturing licensing?
Where process or formulation IP exists, new supply entrants typically need:
- Licensing access to protected steps
- Alternative design-around processes
- Permission to manufacture using non-infringing methods
- Approval under applicable regulatory manufacturing change pathways
Key Takeaways
- A supplier map for AMMONIA N-13 cannot be produced from the label alone.
- Supplier identification requires the exact regulated commercial product identity (manufacturer/marketing authorization, formulation details, and FDA marketing entry alignment).
- Once the exact product identity is pinned, supplier sets can be validated across manufacturing authorization, distribution roles, and operational delivery capacity.
FAQs
- Who regulates AMMONIA N-13 manufacturing and distribution in the US?
- What delivery lead time do radiopharmacies need for AMMONIA N-13 PET scans?
- Can hospitals manufacture AMMONIA N-13 on-site, and how does that change “supplier” terminology?
- What documents do radiopharmacies require for AMMONIA N-13 lot release?
- How can IP and process validation slow AMMONIA N-13 supplier switching?
References
- No citable sources were provided or determinable because the exact AMMONIA N-13 product identity (RLD/NDA/BLA or equivalent marketing designation) is not specified.
